Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 66, 10048-10056, October 15, 2006. doi: 10.1158/0008-5472.CAN-06-1605
© 2006 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koizumi, F.
Right arrow Articles by Matsumura, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koizumi, F.
Right arrow Articles by Matsumura, Y.

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Novel SN-38–Incorporating Polymeric Micelles, NK012, Eradicate Vascular Endothelial Growth Factor–Secreting Bulky Tumors

Fumiaki Koizumi1, Masayuki Kitagawa2, Takahito Negishi1, Takeshi Onda2, Shin-ichi Matsumoto2, Tetsuya Hamaguchi3 and Yasuhiro Matsumura1

1 Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan; 2 Pharmaceutical Research Laboratories, Research and Development Group, Nippon Kayaku Co., Ltd, Kita-ku, Tokyo, Japan; and 3 Department of Medicine, National Cancer Center Hospital, Tyuo-ku, Tokyo, Japan

Requests for reprints: Yasuhiro Matsumura, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan. Phone: 81-4-7134-6857; Fax: 81-4-7134-6857; E-mail: yhmatsum{at}east.ncc.go.jp.

7-Ethyl-10-hydroxy-camptothecin (SN-38), a biological active metabolite of irinotecan hydrochloride (CPT-11), has potent antitumor activity but has not been used clinically because it is a water-insoluble drug. For delivery by i.v. injection, we have successfully developed NK012, a SN-38-releasing nanodevice. The purpose of this study is to investigate the pharmacologic character of NK012 as an anticancer agent, especially in a vascular endothelial growth factor (VEGF)–secreting tumor model. The particle size of NK012 was ~20 nm with a narrow size distribution. NK012 exhibited a much higher cytotoxic effect against lung and colon cancer cell lines as compared with CPT-11. NK012 showed significantly potent antitumor activity against a human colorectal cancer HT-29 xenograft as compared with CPT-11. Enhanced and prolonged distribution of free SN-38 in the tumor was observed after the injection of NK012. NK012 also had significant antitumor activity against bulky SBC-3/Neo (1,533.1 ± 1,204.7 mm3) and SBC-3/VEGF tumors (1,620.7 ± 834.0 mm3) compared with CPT-11. Furthermore, NK012 eradicated bulky SBC-3/VEGF tumors in all mice but did not eradicate SBC-3/Neo tumors. In the drug distribution analysis, an increased accumulation of SN-38 in SBC-3/VEGF tumors was observed as compared with that in SBC-3/Neo tumors. NK012 markedly enhanced the antitumor activity of SN-38, especially in highly VEGF-secreting tumors, and could be a promising SN-38-based formulation. (Cancer Res 2006; 66(20): 10048-56)




This article has been cited by other articles:


Home page
Jpn J Clin OncolHome page
Y. Matsumura
Polymeric Micellar Delivery Systems in Oncology
Jpn. J. Clin. Oncol., December 1, 2008; 38(12): 793 - 802.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Eguchi Nakajima, K. Yanagihara, M. Takigahira, M. Yasunaga, K. Kato, T. Hamaguchi, Y. Yamada, Y. Shimada, K. Mihara, T. Ochiya, et al.
Antitumor Effect of SN-38-Releasing Polymeric Micelles, NK012, on Spontaneous Peritoneal Metastases from Orthotopic Gastric Cancer in Mice Compared with Irinotecan
Cancer Res., November 15, 2008; 68(22): 9318 - 9322.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. W. Card, D. C. Zeldin, J. C. Bonner, and E. R. Nestmann
Pulmonary applications and toxicity of engineered nanoparticles
Am J Physiol Lung Cell Mol Physiol, September 1, 2008; 295(3): L400 - L411.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Sumitomo, F. Koizumi, T. Asano, A. Horiguchi, K. Ito, T. Asano, T. Kakizoe, M. Hayakawa, and Y. Matsumura
Novel SN-38-Incorporated Polymeric Micelle, NK012, Strongly Suppresses Renal Cancer Progression
Cancer Res., March 15, 2008; 68(6): 1631 - 1635.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. Sapra, H. Zhao, M. Mehlig, J. Malaby, P. Kraft, C. Longley, L. M. Greenberger, and I. D. Horak
Novel Delivery of SN38 Markedly Inhibits Tumor Growth in Xenografts, Including a Camptothecin-11-Refractory Model
Clin. Cancer Res., March 15, 2008; 14(6): 1888 - 1896.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.